Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical tapinarof (benvimod) for localized scleroderma
ChiCTR2100046872Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tapinarof in morphea, sponsored by The Second Xiangya Hospital. Primary endpoints: Modified localized scleroderma skin severity index (mLoSSI) and Cutaneous induration. Started Jun 2021; status: recruiting.
02
Drugs
tapinarof
03
Conditions
morphea
Beyond the preview
Go deeper on ChiCTR2100046872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046872.